What is it about?
To systematically evaluate the efficacy and safety of ustekinumab versus placebo for psoriasis.
Featured Image
Why is it important?
Psoriasis is a chronic, recurrent skin disease that affects approximately 2–3% of the world's population, and can significantly impair patients' wellbeing and their physical and mental functioning.
Perspectives
Our results indicate that ustekinumab is safe for patients with moderate to severe plaque psoriasis over a period of 5 years, and it is effective after 12 weeks. There was no significant superiority in efficacy between the 45 mg and 90 mg doses for short-term therapy. Results of the long-term safety evaluation are consistent with short-term reports of ustekinumab safety. More long-term studies and RCTs are needed to validate these results.
meng yang
Read the Original
This page is a summary of: Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis, Clinical and Experimental Dermatology, July 2014, Wiley,
DOI: 10.1111/ced.12390.
You can read the full text:
Contributors
The following have contributed to this page
